International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies

Globally, blood safety interventions have been successful in mitigating risk of the major transfusion‐transmitted (TT) viruses. However, strategies that address risk from parasites are comparatively limited. TT parasites are often regional in nature, posing unique challenges; we sought to understand their impact on blood safety.

[1]  A. Tobian,et al.  Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low‐resource settings , 2018, Vox sanguinis.

[2]  M. Fearon,et al.  Residual risk of HIV, HCV and HBV in Canada. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[3]  C. Riera,et al.  The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood , 2017, Transfusion.

[4]  S. Stramer,et al.  Screening for Babesia microti in the U.S. Blood Supply. , 2016, The New England journal of medicine.

[5]  C. Niederhauser,et al.  Selective Testing of At-Risk Blood Donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland , 2016, Transfusion Medicine and Hemotherapy.

[6]  P. Hotez,et al.  Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa , 2016, PLoS neglected tropical diseases.

[7]  J. Allain,et al.  Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial , 2016, The Lancet.

[8]  E. Slot,et al.  Risk Factors and Screening for Trypanosoma cruzi Infection of Dutch Blood Donors , 2016, PloS one.

[9]  C. Riera,et al.  Transfusion‐transmitted leishmaniasis: a practical review , 2016, Transfusion.

[10]  L. R. Petersen,et al.  Zika Virus. , 2016, The New England journal of medicine.

[11]  S. Kleinman,et al.  Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation , 2015, Transfusion.

[12]  G. Foster,et al.  Keeping Blood Transfusion Safe From West Nile Virus: American Red Cross Experience, 2003 to 2012. , 2015, Transfusion medicine reviews.

[13]  W. Steele,et al.  The Epidemiology of Imported Malaria and Transfusion Policy in 5 Nonendemic Countries. , 2015, Transfusion medicine reviews.

[14]  K. Mørch,et al.  Severe human Babesia divergens infection in Norway. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[15]  R. Goodrich,et al.  Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light , 2015, Transfusion.

[16]  Jia-Fu Jiang,et al.  Epidemiological, clinical, and laboratory characteristics of 48 cases of "Babesia venatorum" infection in China: a descriptive study. , 2015, The Lancet. Infectious diseases.

[17]  A. Cascio,et al.  Transfusion transmitted leishmaniasis. What to do with blood donors from endemic areas? , 2014, Travel medicine and infectious disease.

[18]  P. V. Van Caeseele,et al.  The first case of locally acquired tick-borne Babesia microti infection in Canada , 2014, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[19]  G. Foster,et al.  Investigational screening for Babesia microti in a large repository of blood donor samples from nonendemic and endemic areas of the United States , 2014, Transfusion.

[20]  S. Brubaker,et al.  Trypanosoma cruzi Survival following Cold Storage: Possible Implications for Tissue Banking , 2014, PloS one.

[21]  K. Yasukawa.  Blood donor screening for Trypanosoma cruzi infection in Japan , 2014, Transfusion.

[22]  R. Goodrich,et al.  Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood , 2012, Transfusion.

[23]  B. Herwaldt,et al.  Transfusion-Associated Babesiosis in the United States: A Description of Cases , 2011, Annals of Internal Medicine.

[24]  Z. Yadón,et al.  Chagas disease: a Latin American health problem becoming a world health problem. , 2010, Acta tropica.

[25]  M. Steiert,et al.  Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components , 2008, Transfusion.

[26]  M. Kiehntopf,et al.  First confirmed autochthonous case of human Babesia microti infection in Europe , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[27]  M. Fresno,et al.  The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy‐coat platelets , 2007, Transfusion.

[28]  M. Shimoyama,et al.  [First documentation of transfusion-associated babesiosis in Japan]. , 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[29]  Napier.  Guide to the Preparation, Use and Quality Assurance of Blood Components. , 1998 .